Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Completed · Phase 3

Conditions studied: Porphyria Cutanea Tarda

In brief

To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda. Primary objective - the elimination of all blistering within 6 months of treatment. Secondary objective - decrease in total body iron levels.

Key facts

Study ID
NCT00599326
Run by
University of Texas Southwestern Medical Center
People needed
10
Starts
2008-01-01
Expected to finish
2010-04-01
Last updated by the study team
2014-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.